SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported) January 20, 1999
------------------------
PEDIATRIX MEDICAL GROUP, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Florida
- --------------------------------------------------------------------------------
(State or other jurisdiction of incorporation)
0-26762 65-0271219
------------------------- ---------------------------------
(Commission File Number) (IRS Employer Identification No.)
1455 North Park Drive
Ft. Lauderdale, Florida 33326
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (954) 384-0175
-------------
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
1
<PAGE>
Item 5. Other Events
On January 20, 1999, Pediatrix Medical Group, Inc. (the "Registrant")
announced a two-for-one split of the Registrant's common stock. A copy
of the press release issued by the Registrant on January 20, 1999 is
attached as Exhibit 99.1 hereto and incorporated by reference herein.
Item 7. Financial Statements and Exhibits
(a) Financial Statements of Business Acquired.
Not Applicable.
(b) Pro Forma Financial Information.
Not Applicable.
(c) Exhibits
99.1 Press Release of the Registrant dated January 20, 1999.
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PEDIATRIX MEDICAL GROUP, INC.
Date: February 1, 1999 By: /s/ Karl B. Wagner
----------------------------
Karl B. Wagner
Chief Financial Officer
3
<PAGE>
EXHIBIT INDEX
-------------
99.1 Press release of the Registrant dated January 20, 1999.
FORT LAUDERDALE, FLORIDA, January 20, 1999--Pediatrix Medical Group, Inc.,
(NYSE:PDX) today announced that its Board of Directors authorized a two-for-one
split of the Company's common stock for shareholders of record on February 2,
1999. The distribution date for the shares will be after the market closes on
February 26, 1999.
There were approximately 16 million shares of Pediatrix common stock
outstanding, on a fully-diluted basis, at December 31, 1998.
"We are encouraged that this action will improve the liquidity of our common
stock, making shares of Pediatrix more appealing to a broader investor base,"
said Roger J. Medel, M.D., President and Chief Executive Officer of Pediatrix.
"We are confident that our national physician group remains attractive to both
neonatologists and perinatologists who join Pediatrix to participate in
value-added clinical programs and to shed the administrative burdens associated
with operating a smaller group practice."
Pediatrix was founded in 1979 and has evolved as a national physician group
specializing in neonatal and perinatal care. Pediatrix is the nation's largest
provider of physician services to hospital-based neonatal intensive care units
(NICUs). During 1998, Pediatrix added 27 NICUs by a combination of acquisitions
and internal marketing efforts and now provides services to more than 120 NICUs
nationwide.
Obstetrix Medical Group, a Pediatrix subsidiary, provides perinatal physician
services in a total of eight U.S. markets.
Combined, Pediatrix employs approximately 345 physicians. Additional
information is available on the Internet: www.pediatrix.com.
Except for historical information, this press release contains certain
forward-looking statements that involve risk and uncertainties that may cause
actual results to differ materially from the statements made. Such factors
include, but are not limited to, changing market conditions, the ability to
successfully identify suitable acquisition candidates and to complete those
acquisitions on favorable terms and other risks detailed from time to time by
the Company or in its filings with the U.S. Securities and Exchange Commission.
